bioAffinity Technologies, Inc.
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -9.60 | $2M | -$3M |
| 2026 Q1 | -12.15 | $1M | -$3M |
| 2025 Q4 | -27.30 | $2M | -$2M |
| 2025 Q3 | -71.10 | $1M | -$2M |
| 2025 Q2 | -76.05 | $1M | -$3M |
| 2025 Q1 | -72.00 | $2M | -$2M |
| 2024 Q4 |
| -94.50 |
| $2M |
| -$2M |
| 2024 Q3 | -72.00 | $2M | -$2M |